REPLICATION-DEFICIENT RECOMBINANT VIRUS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND THE USES THEREOF

A replication-deficient recombinant virus, comprising human fusion gene LFA3-Fc under the control of promoter. The human fusion gene LFA3-Fc is fused by soluble extracellular domain of human LFA3 and Fc fragment of human IgG. Pharmaceutical composition against psoriasis, consisting of the replicatio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHANG, RENHUAI, LI, HONGGUANG, HE, BO, TANG, QI, ZHONG, SHAODONG, YANG, YONG, HAN, WEIYUE, WEN, YALEI, HE, KAI, YANG, LIMING
Format:	Patent
Sprache:	chi ; eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A replication-deficient recombinant virus, comprising human fusion gene LFA3-Fc under the control of promoter. The human fusion gene LFA3-Fc is fused by soluble extracellular domain of human LFA3 and Fc fragment of human IgG. Pharmaceutical composition against psoriasis, consisting of the replication-deficient virus and pharmaceutical acceptable dressing. Injection of pharmaceutical composition against psoriasis produced by the method according to the present invention can make the target protein be expressed in vivo for long time, therefore administration times can be reduced. L'invention porte sur un virus recombinant déficient en réplication, comprenant un gène de fusion humain LFA3-Fc sous le contrôle d'un promoteur. Le gène de fusion humain LFA3-Fc est fusionné par domaine extracellulaire soluble de LFA3 humain et d'un fragment Fc d'une IgG humaine. L'invention porte également sur une composition pharmaceutique contre le psoriasis, comprenant le virus déficient en réplication et un pansement pharmaceutiq